All In Biotech

Drug Trial Radar · NCT06975618

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)

A Phase I/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CYH33 (a Selective PI3Kα Inhibitor) in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 141 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

141

Planned (sponsor's estimate)

Start

Aug 22, 2023

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Haihe Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
May 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, open-label, single arm, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CYH33 in patients with PIK3CA-related overgrowth spectrum (PROS) and PIK3CA-related vascular malformations (PRVM)

Conditions

  • PIK3CA-Related Overgrowth Spectrum (PROS)
  • PIK3CA-related Vascular Malformations (PRVM)

Interventions

  • CYH33Drug

    CYH33: Participants will receive oral CYH33 once daily. The starting dose for adults in Phase I is 10 mg QD; adolescents begin at 5 mg QD. In Phase II, patients will receive RP2D determined in the Phase I study.

  • PlaceboDrug

    Placebo: Matching placebo tablets will be administered once daily during the double-blind period of the Phase II PRVM cohort. Patients randomized to placebo will switch to CYH33 at the end of the blinded phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: The maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D)Time frame: 27 weeks
  2. Phase II PROS Cohort: BIRC-assessed objective response rate (ORR) at Week 24Time frame: Baseline to 24weeks
  3. Phase II PRVM Cohort: BIRC-assessed objective response rate (ORR) at Week 24Time frame: Baseline to 24weeks

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Capital Center for Children's Health, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Plastic Surgery Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • Guangzhou Women and Children's Medical Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Shanghai Ninth People Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Gifu University Hospital

    Gifu, Japan · Recruiting

  • Tonan Hospital

    Sapporo, Hokkaido, Japan · Recruiting

  • National Hospital Organization Kobe Medical Center

    Kobe, Hyōgo, Japan · Recruiting

  • Yokohama City University Hospital

    Yokohama, Kanagawa, Japan · Recruiting

  • Tohoku University Hospital

    Sendai, Miyagi, Japan · Recruiting

  • Shinshu University Hospital

    Matsumoto, Nagano, Japan · Recruiting

  • Kyorin University Hospital

    Mitaka, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.